Introduction
Pelvic exenteration (PE) is a radical and life-altering surgery often performed as a last resort for patients with locally advanced intrapelvic malignancies. This extensive procedure involves the removal of several organs within the pelvic cavity and often leaves patients with significant physical and emotional challenges. The success of this operation depends not only on the removal of cancerous tissues but also on effective pelvic floor reconstruction to optimize the patient’s quality of life post-surgery. This article reviews a 12-year study published in the European Journal of Surgical Oncology that highlights the efficacy of the transverse myocutaneous gracilis (TMG) flap technique in pelvic floor reconstruction after pelvic exenteration.
Background
Pelvic exenteration is considered the only curative option for certain types of locally advanced, residual, or recurrent intrapelvic tumors. However, this procedure carries a high morbidity rate and a complex postoperative course. Reconstruction of the pelvic floor and vulvovaginal defects is crucial, not only for the containment of pelvic organs and prevention of herniation but also for restoring the anatomy and function as closely as possible to their pre-operative state.
The Study
Researchers led by Dr. Juha Kiiski at Tampere University Hospital and the University of Tampere conducted a retrospective chart review to assess surgical and oncological outcomes after PE. The study, entitled “Transverse Myocutaneous Gracilis Flap Reconstruction Is Feasible After Pelvic Exenteration: 12-Year Surgical and Oncological Results,” involved 39 patients who underwent PE between 2007 and 2019.
Findings
Of the 39 patients, 25 underwent reconstruction using TMG flaps. The interesting revelation of this study was that TMG flaps did not contribute to increased complication rates. In fact, the complication rate was lower (65.4%) for patients with TMG flap reconstruction compared to those without it (84.6%), although this difference was not statistically significant (p = 0.191). Additionally, although patients with major complications had longer hospital stays, these complications did not have a significant impact on overall survival (OS).
The study reported promising survival rates, with 1- and 5-year OS being 72% and 48%, respectively. In terms of prognostic factors, lymph node metastasis and positive surgical margins were identified as risk factors, substantially impacting OS.
Significance of TMG Flaps
The TMG flap is favored in many surgical centers due to its reduced donor site morbidity and the fact that it does not interfere with the construction of an enterostomy. This makes it an ideal option for many patients who have undergone PE. TMG flaps use tissue from the gracilis muscle, a thin muscle found on the inner thigh, which can be transplanted to the pelvic area to provide structural support and cover the defect left by the removal of pelvic organs.
The researchers concluded that TMG flap reconstructions of pelvic floor and vulvovaginal defects after PE were not only feasible but also reliable in the long-term management of patients with advanced pelvic malignancies. The TMG flap procedure has become the preferred option in many institutions, including Tampere University Hospital due to its favorable outcomes.
Implications for Patients and Clinicians
For patients facing pelvic exenteration, the prospect of TMG flap reconstruction offers a glimmer of hope for a better postoperative quality of life. For clinicians, the findings emphasize the need for a multidisciplinary approach in managing complex cancer surgeries – from careful pre-operative planning to meticulous surgical execution and dedicated post-operative care.
These findings also have significant implications for healthcare systems, as they suggest a method that potentially reduces hospital stay durations, which can translate into cost savings and improved patient turnover rates.
DOI and References
DOI: 10.1016/j.ejso.2019.04.021
1. Kiiski, J., Räikkönen, K., Vuento, M. H., Hyöty, M. K., Kallio, J., Kuokkanen, H. O., & Kaartinen, I. S. (2019). Transverse myocutaneous gracilis flap reconstruction is feasible after pelvic exenteration: 12-year surgical and oncological results. European Journal of Surgical Oncology, 45(9), 1632–1637. https://doi.org/10.1016/j.ejso.2019.04.021
2. Maggiori, L., & Panis, Y. (2013). Pelvic exenteration for colorectal malignancies. European Journal of Surgical Oncology, 39(12), 1383-1390.
3. Sunesen, K. G., Buntzen, S., Tei, T., & Lindegaard, J. C. (2009). Perioperative complications and mortality after pelvic exenteration for rectal cancer. Diseases of the Colon & Rectum, 52(5), 891–896.
4. Peacock, O., & Daniels, I. R. (2017). The role of pelvic exenteration surgery and the evidence for it. Clinical Oncology, 29(4), 241-244.
5. Ulrich, D., Rozen, W. M., Grinsell, D., Ashton, M. W., & Taylor, G. I. (2011). The anatomical and neurovascular basis for the interposition flap in autologous breast reconstruction. Journal of Plastic, Reconstructive & Aesthetic Surgery, 64(4), 497-504.
Keywords
1. Pelvic Exenteration Survival Rates
2. Transverse Myocutaneous Gracilis Flap
3. Pelvic Floor Reconstruction Surgery
4. Vaginal Reconstruction Techniques
5. Oncological Outcomes Post-Exenteration